Background: Recent pilot trials have demonstrated the safety of transplanting HCV-viremic kidneys into HCV-seronegative recipients. However, it remains unclear if allograft function is impacted by donor HCV-viremia or recipient HCV-serostatus.
Methods: We used national United States registry data to examine trends in HCV-viremic kidney use between 4/1/2015 and 3/31/2019. We applied advanced matching methods to compare eGFR for similar kidneys transplanted into highly similar recipients of kidney transplants.
Results: Over time, HCV-seronegative recipients received a rising proportion of HCV-viremic kidneys. During the first quarter of 2019, 200 HCV-viremic kidneys were transplanted into HCV-seronegative recipients, versus 69 into HCV-seropositive recipients, while 105 HCV-viremic kidneys were discarded. The probability of HCV-viremic kidney discard has declined over time. Kidney transplant candidates willing to accept a HCV-seropositive kidney increased from 2936 to 16,809 from during this time period. When transplanted into HCV-seronegative recipients, HCV-viremic kidneys matched to HCV-non-viremic kidneys on predictors of organ quality, except HCV, had similar 1-year eGFR (66.3 versus 67.1 ml/min per 1.73 m2, P=0.86). This was despite the much worse kidney donor profile index scores assigned to the HCV-viremic kidneys. Recipient HCV-serostatus was not associated with a clinically meaningful difference in 1-year eGFR (66.5 versus 71.1 ml/min per 1.73 m2, P=0.056) after transplantation of HCV-viremic kidneys.
Conclusions: By 2019, HCV-seronegative patients received the majority of kidneys transplanted from HCV-viremic donors. Widely used organ quality scores underestimated the quality of HCV-viremic kidneys based on 1-year allograft function. Recipient HCV-serostatus was also not associated with worse short-term allograft function using HCV-viremic kidneys.
Keywords: end stage kidney disease; hepatitis; kidney transplantation; transplantation.
Copyright © 2019 by the American Society of Nephrology.
Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected RecipientsMH Eckman et al. Am J Kidney Dis. PMID 32081494.Transplanting kidneys from HCV-viremic donors into HCV-uninfected recipients increased quality-adjusted life expectancy and reduced costs compared with a strategy of tran …
Short-term Outcomes of Deceased Donor Renal Transplants of HCV Uninfected Recipients From HCV Seropositive Nonviremic Donors and Viremic Donors in the Era of Direct-Acting AntiviralsRM La Hoz et al. Am J Transplant 19 (11), 3058-3070. PMID 31207073.The United States opioid use epidemic over the past decade has coincided with an increase in hepatitis C virus (HCV) positive donors. Using propensity score matching, and …
Utilization Rates and Clinical Outcomes of Hepatitis C Positive Donor Hearts in the Contemporary EraS Madan et al. J Heart Lung Transplant 38 (9), 907-917. PMID 31495408.Recipients of HCV-viremic and HCV Ab+ nonviremic donor hearts had equivalent risk of PGF and 1-year mortality compared with recipients of HCV-naive donor heart …
Transplantation of Kidneys From HCV-positive Donors: A Safe Strategy?F Fabrizi et al. J Nephrol 16 (5), 617-25. PMID 14733406. - ReviewHepatitis C Virus (HCV) infection is the most important cause of liver disease after renal transplantation (RT). The impact of HCV on patient and graft survival after RT …
Belatacept for Kidney Transplant RecipientsP Masson et al. Cochrane Database Syst Rev 2014 (11), CD010699. PMID 25416857. - ReviewThere is no evidence of any difference in the effectiveness of belatacept and CNI in preventing acute rejection, graft loss and death, but treatment with belatacept is as …
Cited by 1 PubMed Central articles
Transplantation of Kidneys From HCV Viremic Donors in the United States: A Missed Opportunity to Inform Clinical Decision Making and Health PolicyJS Gill et al. J Am Soc Nephrol 30 (10), 1778-1780. PMID 31570540.